未经证实:神经内分泌乳腺癌(NEBC)是一种罕见的乳腺癌亚组,占所有浸润性乳腺癌的2-5%。此回顾性分析的目的是呈现和分析我们自己的主要NEBC数据。
未经批准:我们回顾性分析了临床,病态,与925例浸润性导管癌(IDC/NOS)患者相比,2008年至2019年间诊断为神经内分泌分化型乳腺癌的36例患者的影像学特征以及文献综述。
未经批准:在这项研究中,36例神经内分泌分化型乳腺癌患者和961例(IDC/NOS)患者,作为比较组,在2008年至2019年之间确定。在NEBC患者中,绝经前7例,绝经后29例.超声(USG),磁共振,和我们医院提供的乳房X线摄影(MMG)图像,在MMG中检测到高密度肿块,不规则(77%),小叶(80%)和针状边缘(63%),没有不对称和结构扭曲。钙化不如浸润性乳腺癌常见,仅出现在四名患者中(17%)。当NEBC与导管癌进行比较时(n=925),NEBC更常为人类表皮生长因子受体2阴性(p=0.039),雌激素受体阳性(p=0.05),孕激素受体阳性(0.03),NEBC患者年龄较大(p=0.02)。年龄,grade,转移状态,淋巴结数目,和分子类型被确定为显著影响两组生存的预后因素(p<0.05)。
未经证实:NEBC是一种在组织病理学和放射学上都与其他乳腺癌亚型不同的亚型。神经内分泌分化可能是未来一个重要的预测指标。
UNASSIGNED: Neuroendocrine breast carcinoma (NEBC) is a rare subgroup of breast cancer, which makes up 2-5% of all invasive breast cancers. The aim of this retrospective analysis is to present and analyze our own data of primary NEBCs.
UNASSIGNED: We retrospectively analyzed clinical, pathological, and radiological characteristics of 36 patients diagnosed with neuroendocrine differentiated breast cancer between 2008 and 2019 compared to that of 925 patients with invasive ductal carcinoma (IDC/NOS) along with a literature
review.
UNASSIGNED: In this study, 36 patients with neuroendocrine differentiated breast carcinoma and 961 patients with (IDC/NOS), as the comparison group, were identified between 2008 and 2019. In NEBC patients, seven were premenopausal and 29 postmenopausal. Patients whose ultrasound (USG), magnetic resonance, and mammographic (MMG) images available in our hospital, high-density masses were detected in the MMG with irregular (77%), microlobulated (80%) and spiculated margins (63%), unaccompanied by asymmetry and structural distortion. Calcifications were less common than invasive breast cancer, present only in four patients (17%). When NEBC were compared to ductal carcinomas (n=925), NEBC were more often human epidermal growth factor receptor 2 negative (p=0.039), estrogen receptor positive (p=0.05), progesterone receptor positive (0.03), and the NEBC patients were older (p=0.02). Age, grade, metastatic status, lymph node number, and molecular type were identified as prognostic factors that significantly affect survival in both groups (p<0.05).
UNASSIGNED: NEBC is a subtype that is both histopathologically and radiologically distinct from other breast cancer subtypes, and neuroendocrine differentiation may be an important predictive marker in the future.